Clinical and demographic characteristics and two-year efficacy and safety data of 508 multiple sclerosis patients with fingolimod treatment (vol 60, pg 23, 2023)

Terzi, MuratHelvacı, Elif MerveŞen, SedatBoz, CavitÇilingir, VedatAkçalı, AylinBeckmann, YeşimUzunköprü, CihatSözer, GökçeTerzi, Yüksel2023-08-252023-08-252023Terzi, M., Helvacı, E. M., Şen, S., Boz, C., Çilingir, V., Akçalı, A. ... Terzi, Y. (2023). Clinical and demographic characteristics and two-year efficacy and safety data of 508 multiple sclerosis patients with fingolimod treatment (vol 60, pg 23, 2023). Archives of Neuropsychiatry, 60(2), 190-190. https://dx.doi.org/10.29399/npa.284991300-06671309-4866https://dx.doi.org/10.29399/npa.28499https://hdl.handle.net/20.500.12511/11366Copyright of Archives of Neuropsychiatry / Noropsikiatri Arsivi is the property of Turkish Association of Neuropsychiatry and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.eninfo:eu-repo/semantics/embargoedAccessEfficacyFingolimodMultiple SclerosisSafetyClinical and demographic characteristics and two-year efficacy and safety data of 508 multiple sclerosis patients with fingolimod treatment (vol 60, pg 23, 2023)Other60219019010.29399/npa.28499Q400102164210001736911568